Cargando…
Preclinical Studies and Drug Combination of Low-Cost Molecules for Chagas Disease
Chagas disease is caused by the protozoan Trypanosoma cruzi (T. cruzi). It remains the major parasitic disease in Latin America and is spreading worldwide, affecting over 10 million people. Hundreds of new compounds with trypanosomicidal action have been identified from different sources such as syn...
Autores principales: | Aguilera, Elena, Sánchez, Carina, Cruces, María Eugenia, Dávila, Belén, Minini, Lucía, Mosquillo, Florencia, Pérez-Díaz, Leticia, Serna, Elva, Torres, Susana, Schini, Alicia, Sanabria, Luis, Vera de Bilbao, Ninfa I., Yaluff, Gloria, Zolessi, Flavio R., Ceilas, Luis Fabian, Cerecetto, Hugo, Alvarez, Guzmán |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863266/ https://www.ncbi.nlm.nih.gov/pubmed/36678516 http://dx.doi.org/10.3390/ph16010020 |
Ejemplares similares
-
Looking for combination of benznidazole and Trypanosoma cruzi-triosephosphate isomerase inhibitors for Chagas disease treatment
por: Aguilera, Elena, et al.
Publicado: (2018) -
In Vivo Anti-Trypanosoma cruzi Activity of Hydro-Ethanolic Extract and Isolated Active Principles from Aristeguietia glutinosa and Mechanism of Action Studies
por: Varela, Javier, et al.
Publicado: (2014) -
Preclinical Studies in Anti-Trypanosomatidae Drug Development
por: Perdomo, Cintya, et al.
Publicado: (2021) -
A Nature-Inspired Design Yields a New Class of Steroids Against Trypanosomatids
por: Aguilera, Elena, et al.
Publicado: (2019) -
Synthetic Medicinal Chemistry in Chagas’ Disease: Compounds at The Final Stage of “Hit-To-Lead” Phase
por: Cerecetto, Hugo, et al.
Publicado: (2010)